PRAX Quote, Financials, Valuation and Earnings

Geron Corp. has a net margin of -786.27% compared to Praxis Precision Medicines, Inc.'s net margin of -39.02%. Praxis Precision Medicines, Inc.'s return on equity of -67.75% beat Geron Corp.'s return on equity of -29.65%.

Praxis Precision Medicines, Inc. has a consensus price target of $419.13, signalling upside risk potential of 52.55%. On the other hand Geron Corp. has an analysts' consensus of $3.60 which suggests that it could grow by 157.14%. Given that Geron Corp. has higher upside potential than Praxis Precision Medicines, Inc., analysts believe Geron Corp. is more attractive than Praxis Precision Medicines, Inc..

Praxis Precision Medicines, Inc. has a beta of 2.946, which suggesting that the stock is 194.607% more volatile than S&P 500. In comparison Geron Corp. has a beta of 0.567, suggesting its less volatile than the S&P 500 by 43.26%.

Praxis Precision Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines, Inc. pays -- of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend.

Praxis Precision Medicines, Inc. quarterly revenues are --, which are smaller than Geron Corp. quarterly revenues of $47.2M. Praxis Precision Medicines, Inc.'s net income of -$73.9M is lower than Geron Corp.'s net income of -$18.4M. Notably, Praxis Precision Medicines, Inc.'s price-to-earnings ratio is -- while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines, Inc. is 777.63x versus 5.08x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.

GRAIL, Inc. has a net margin of -786.27% compared to Praxis Precision Medicines, Inc.'s net margin of -245.83%. Praxis Precision Medicines, Inc.'s return on equity of -67.75% beat GRAIL, Inc.'s return on equity of -16.84%.

Praxis Precision Medicines, Inc. has a consensus price target of $419.13, signalling upside risk potential of 52.55%. On the other hand GRAIL, Inc. has an analysts' consensus of $105.00 which suggests that it could grow by 14.3%. Given that Praxis Precision Medicines, Inc. has higher upside potential than GRAIL, Inc., analysts believe Praxis Precision Medicines, Inc. is more attractive than GRAIL, Inc..

Praxis Precision Medicines, Inc. has a beta of 2.946, which suggesting that the stock is 194.607% more volatile than S&P 500. In comparison GRAIL, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Praxis Precision Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GRAIL, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines, Inc. pays -- of its earnings as a dividend. GRAIL, Inc. pays out -- of its earnings as a dividend.

Praxis Precision Medicines, Inc. quarterly revenues are --, which are smaller than GRAIL, Inc. quarterly revenues of $36.2M. Praxis Precision Medicines, Inc.'s net income of -$73.9M is higher than GRAIL, Inc.'s net income of -$89M. Notably, Praxis Precision Medicines, Inc.'s price-to-earnings ratio is -- while GRAIL, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines, Inc. is 777.63x versus 22.69x for GRAIL, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

MIRA Pharmaceuticals, Inc. has a net margin of -786.27% compared to Praxis Precision Medicines, Inc.'s net margin of --. Praxis Precision Medicines, Inc.'s return on equity of -67.75% beat MIRA Pharmaceuticals, Inc.'s return on equity of -935.53%.

Praxis Precision Medicines, Inc. has a consensus price target of $419.13, signalling upside risk potential of 52.55%. On the other hand MIRA Pharmaceuticals, Inc. has an analysts' consensus of $17.75 which suggests that it could grow by 1023.42%. Given that MIRA Pharmaceuticals, Inc. has higher upside potential than Praxis Precision Medicines, Inc., analysts believe MIRA Pharmaceuticals, Inc. is more attractive than Praxis Precision Medicines, Inc..

Praxis Precision Medicines, Inc. has a beta of 2.946, which suggesting that the stock is 194.607% more volatile than S&P 500. In comparison MIRA Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Praxis Precision Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MIRA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines, Inc. pays -- of its earnings as a dividend. MIRA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Praxis Precision Medicines, Inc. quarterly revenues are --, which are smaller than MIRA Pharmaceuticals, Inc. quarterly revenues of --. Praxis Precision Medicines, Inc.'s net income of -$73.9M is lower than MIRA Pharmaceuticals, Inc.'s net income of -$22.7M. Notably, Praxis Precision Medicines, Inc.'s price-to-earnings ratio is -- while MIRA Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines, Inc. is 777.63x versus -- for MIRA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

PTC Therapeutics, Inc. has a net margin of -786.27% compared to Praxis Precision Medicines, Inc.'s net margin of 7.53%. Praxis Precision Medicines, Inc.'s return on equity of -67.75% beat PTC Therapeutics, Inc.'s return on equity of --.

Praxis Precision Medicines, Inc. has a consensus price target of $419.13, signalling upside risk potential of 52.55%. On the other hand PTC Therapeutics, Inc. has an analysts' consensus of $81.86 which suggests that it could grow by 4.45%. Given that Praxis Precision Medicines, Inc. has higher upside potential than PTC Therapeutics, Inc., analysts believe Praxis Precision Medicines, Inc. is more attractive than PTC Therapeutics, Inc..

Praxis Precision Medicines, Inc. has a beta of 2.946, which suggesting that the stock is 194.607% more volatile than S&P 500. In comparison PTC Therapeutics, Inc. has a beta of 0.470, suggesting its less volatile than the S&P 500 by 52.999%.

Praxis Precision Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines, Inc. pays -- of its earnings as a dividend. PTC Therapeutics, Inc. pays out -- of its earnings as a dividend.

Praxis Precision Medicines, Inc. quarterly revenues are --, which are smaller than PTC Therapeutics, Inc. quarterly revenues of $211M. Praxis Precision Medicines, Inc.'s net income of -$73.9M is lower than PTC Therapeutics, Inc.'s net income of $15.9M. Notably, Praxis Precision Medicines, Inc.'s price-to-earnings ratio is -- while PTC Therapeutics, Inc.'s PE ratio is 9.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines, Inc. is 777.63x versus 3.62x for PTC Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.